Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22a87fe9e9b122e

Jump to content

Talk:Beclamide

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 20 years ago by Rmky87

I've added this article based on what information I can find on PubMed, Google and Google Book Search. There isn't much out there. I have some unanswered questions:

  • What company developed this drug?
  • Why does it have so many alternative (trade) names?
  • Is anyone still manufacturing it?
  • Is it and has it ever been available on prescription anywhere?
  • Did it get beyond small-scale trials?
  • Why was it abandoned (not effective enought, most likely)?
  • What company developed this drug?
Got me there, for now.
  • Why does it have so many alternative (trade) names?
Because drugs are often released under different names in different countries, and multiple brand names spring up when a drug goes off-patent. The oldest one would seem to be Hibicon. It appears in an abstract from 1951 (PMID 14913640); Nydrane showed up in 1957 (PMID 13426552). I notice that the earliest Nydrane ones all come from the British Medical Journal, and that the earliest Hibicon ones were published in things like, "Transactions of the American Neurological Association", and "A. M. A. archives of neurology and psychiatry". Keep in mind that the date shown is the publication date, not the date of submission.
  • Is anyone still manufacturing it?
Don't know, yet.
  • Is it and has it ever been available on prescription anywhere?
I have never heard of a drug with known anticonvulsant properties (and enough of them to matter) being available over the counter. That's just asking for trouble.
  • Did it get beyond small-scale trials?
For epilepsy? I would assume so, as it was sold under all those names in all those places.
  • Why was it abandoned (not effective enought, most likely)?
Maybe it simply became unprofitable. I don't know...--Rmky87 21:15, 16 February 2006 (UTC)Reply